Recipient Age for Liver Transplantation: Should It Be Limited? A Propensity Score Matching Analysis of a Large European Series.


Journal

Transplantation proceedings
ISSN: 1873-2623
Titre abrégé: Transplant Proc
Pays: United States
ID NLM: 0243532

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 26 01 2020
accepted: 05 02 2020
pubmed: 11 5 2020
medline: 3 11 2020
entrez: 11 5 2020
Statut: ppublish

Résumé

The demand for older patients not to be denied access to liver transplantation (LT) has intensified as the European population continues to live longer and maintains better health. This study aims to ascertain the impact of recipient age on the post-LT survival in 2 well-balanced populations at Vall d'Hebron University Hospital. From January 1990 to December 2016, LT recipients (young group: 50-65 years of age; elderly group: >65 years of age) were compared by means of a propensity score matching (PSM) method. Prior to PSM, graft survival and patient survival were worse for the elderly group (P < .001). In 1126 LT recipients, a caliper width of 0.01 was used based on the donor (age, sex, cause of donor death, and donor intensive care unit stay) and recipient covariates (sex, body mass index, indication for LT, intraoperative blood transfusion, cardiovascular risk factors, and Model for End-Stage Liver Disease [MELD]-Era). After PSM, 206 patients were matched; 1-, 5-, and 10-year patient survival rates were 77%, 63%, and 52% vs 80%, 64%, and 45% (P = .50) for young vs elderly recipients, respectively. Similar graft survival rates were observed in both groups (P = .42). Advanced age alone should not exclude patients from LT.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
The demand for older patients not to be denied access to liver transplantation (LT) has intensified as the European population continues to live longer and maintains better health.
AIM OBJECTIVE
This study aims to ascertain the impact of recipient age on the post-LT survival in 2 well-balanced populations at Vall d'Hebron University Hospital.
METHODS METHODS
From January 1990 to December 2016, LT recipients (young group: 50-65 years of age; elderly group: >65 years of age) were compared by means of a propensity score matching (PSM) method.
RESULTS RESULTS
Prior to PSM, graft survival and patient survival were worse for the elderly group (P < .001). In 1126 LT recipients, a caliper width of 0.01 was used based on the donor (age, sex, cause of donor death, and donor intensive care unit stay) and recipient covariates (sex, body mass index, indication for LT, intraoperative blood transfusion, cardiovascular risk factors, and Model for End-Stage Liver Disease [MELD]-Era). After PSM, 206 patients were matched; 1-, 5-, and 10-year patient survival rates were 77%, 63%, and 52% vs 80%, 64%, and 45% (P = .50) for young vs elderly recipients, respectively. Similar graft survival rates were observed in both groups (P = .42).
CONCLUSIONS CONCLUSIONS
Advanced age alone should not exclude patients from LT.

Identifiants

pubmed: 32387080
pii: S0041-1345(20)30258-X
doi: 10.1016/j.transproceed.2020.02.061
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1442-1449

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Concepción Gómez-Gavara (C)

Department of HPB Surgery and Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: concepcion.gomez@vhebron.net.

Ramón Charco (R)

Department of HPB Surgery and Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain.

Ingrid Tapiolas (I)

Department of HPB Surgery and Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain; Autonoma University Barcelona, Barcelona, Spain.

Núria Ridaura (N)

Department of HPB Surgery and Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain; Autonoma University Barcelona, Barcelona, Spain.

Isabel Campos-Varela (I)

Liver Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.

Cristina Dopazo (C)

Department of HPB Surgery and Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain; Autonoma University Barcelona, Barcelona, Spain.

Elizabeth Pando (E)

Department of HPB Surgery and Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain.

Mireia Caralt (M)

Department of HPB Surgery and Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain.

Ernest Hidalgo (E)

Department of HPB Surgery and Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain.

Lluís Castells (L)

Liver Unit, Department of Internal Medicine, Vall d'Hebron University Hospital, Barcelona, Spain.

Itxarone Bilbao (I)

Department of HPB Surgery and Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain; Autonoma University Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH